AI Article Synopsis
- Heart failure (HF) is a serious condition involving problems with the heart's ability to pump or fill with blood, leading to high rates of illness and death worldwide.
- Heart failure with preserved ejection fraction (HFpEF), where the heart's ability to pump is still relatively normal (LVEF ≥50%), affects more than half of those with heart failure and is becoming more common.
- Recent studies suggest that sodium-glucose cotransporter 2 (SGLT2) inhibitors are effective in treating HFpEF, potentially reducing hospitalizations and mortality, which this review article discusses through current research and clinical trials.
Article Abstract
Heart failure (HF) is a clinical syndrome due to either functional or structural impairment of the ventricular pump or filling, representing a major cause of global morbidity and mortality. Heart failure with preserved ejection fraction (HFpEF), characterized by a left ventricular ejection fraction (LVEF) of ≥50%, constitutes over half of the HF population, with a rising prevalence. Until recently, therapeutic options in treating HFpEF and reducing hospitalization and mortality remained limited. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promising results in this patient population. This review article explores current literature and significant clinical trials investigating the impact of sodium- SGLT2 inhibitors in patients with HFpEF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cpcardiol.2024.102388 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!